nodes	percent_of_prediction	percent_of_DWPC	metapath
Montelukast—CYP2C9—Teniposide—lymphatic system cancer	0.137	0.35	CbGbCtD
Montelukast—CYP3A4—Cytarabine—lymphatic system cancer	0.0808	0.207	CbGbCtD
Montelukast—CYP3A4—Teniposide—lymphatic system cancer	0.0796	0.203	CbGbCtD
Montelukast—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0557	0.142	CbGbCtD
Montelukast—CYP3A4—Vincristine—lymphatic system cancer	0.0383	0.0979	CbGbCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0045	0.00739	CcSEcCtD
Montelukast—Pneumonia—Fludarabine—lymphatic system cancer	0.00444	0.00729	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00437	0.00719	CcSEcCtD
Montelukast—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00434	0.00714	CcSEcCtD
Montelukast—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00432	0.00711	CcSEcCtD
Montelukast—Infection—Mechlorethamine—lymphatic system cancer	0.00431	0.00709	CcSEcCtD
Montelukast—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00425	0.00699	CcSEcCtD
Montelukast—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00422	0.00693	CcSEcCtD
Montelukast—Epistaxis—Fludarabine—lymphatic system cancer	0.00416	0.00684	CcSEcCtD
Montelukast—Sinusitis—Fludarabine—lymphatic system cancer	0.00414	0.0068	CcSEcCtD
Montelukast—Injury—Carmustine—lymphatic system cancer	0.00399	0.00655	CcSEcCtD
Montelukast—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00394	0.00647	CcSEcCtD
Montelukast—Pharyngitis—Fludarabine—lymphatic system cancer	0.00393	0.00646	CcSEcCtD
Montelukast—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00374	0.00615	CcSEcCtD
Montelukast—Agitation—Teniposide—lymphatic system cancer	0.0036	0.00592	CcSEcCtD
Montelukast—Liver disorder—Methotrexate—lymphatic system cancer	0.00343	0.00564	CcSEcCtD
Montelukast—Pneumonia—Bleomycin—lymphatic system cancer	0.00325	0.00535	CcSEcCtD
Montelukast—Oedema—Teniposide—lymphatic system cancer	0.0032	0.00526	CcSEcCtD
Montelukast—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0032	0.00526	CcSEcCtD
Montelukast—Infection—Teniposide—lymphatic system cancer	0.00318	0.00523	CcSEcCtD
Montelukast—Agitation—Fludarabine—lymphatic system cancer	0.00317	0.00521	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00315	0.00518	CcSEcCtD
Montelukast—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00313	0.00515	CcSEcCtD
Montelukast—Pruritus—Mechlorethamine—lymphatic system cancer	0.00307	0.00505	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00307	0.00504	CcSEcCtD
Montelukast—Cough—Fludarabine—lymphatic system cancer	0.00301	0.00494	CcSEcCtD
Montelukast—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.003	0.00494	CcSEcCtD
Montelukast—Convulsion—Fludarabine—lymphatic system cancer	0.00299	0.00491	CcSEcCtD
Montelukast—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00297	0.00488	CcSEcCtD
Montelukast—Myalgia—Fludarabine—lymphatic system cancer	0.00293	0.00482	CcSEcCtD
Montelukast—Arthralgia—Fludarabine—lymphatic system cancer	0.00293	0.00482	CcSEcCtD
Montelukast—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00289	0.00475	CcSEcCtD
Montelukast—Pneumonia—Carmustine—lymphatic system cancer	0.00284	0.00467	CcSEcCtD
Montelukast—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00281	0.00462	CcSEcCtD
Montelukast—Oedema—Fludarabine—lymphatic system cancer	0.00281	0.00462	CcSEcCtD
Montelukast—Infection—Fludarabine—lymphatic system cancer	0.00279	0.00459	CcSEcCtD
Montelukast—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00277	0.00455	CcSEcCtD
Montelukast—Vomiting—Mechlorethamine—lymphatic system cancer	0.00276	0.00454	CcSEcCtD
Montelukast—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00276	0.00453	CcSEcCtD
Montelukast—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00275	0.00453	CcSEcCtD
Montelukast—Rash—Mechlorethamine—lymphatic system cancer	0.00274	0.0045	CcSEcCtD
Montelukast—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00274	0.0045	CcSEcCtD
Montelukast—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00274	0.00449	CcSEcCtD
Montelukast—Pneumonia—Vincristine—lymphatic system cancer	0.00271	0.00445	CcSEcCtD
Montelukast—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00264	0.00434	CcSEcCtD
Montelukast—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00264	0.00434	CcSEcCtD
Montelukast—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00262	0.00431	CcSEcCtD
Montelukast—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00262	0.0043	CcSEcCtD
Montelukast—Bone disorder—Methotrexate—lymphatic system cancer	0.00259	0.00425	CcSEcCtD
Montelukast—Nausea—Mechlorethamine—lymphatic system cancer	0.00258	0.00424	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00256	0.00421	CcSEcCtD
Montelukast—Jaundice—Mitoxantrone—lymphatic system cancer	0.00256	0.0042	CcSEcCtD
Montelukast—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00255	0.00419	CcSEcCtD
Montelukast—Urticaria—Teniposide—lymphatic system cancer	0.00254	0.00418	CcSEcCtD
Montelukast—Body temperature increased—Teniposide—lymphatic system cancer	0.00253	0.00416	CcSEcCtD
Montelukast—Abdominal pain—Teniposide—lymphatic system cancer	0.00253	0.00416	CcSEcCtD
Montelukast—Paraesthesia—Fludarabine—lymphatic system cancer	0.00253	0.00415	CcSEcCtD
Montelukast—Hallucination—Carmustine—lymphatic system cancer	0.00252	0.00414	CcSEcCtD
Montelukast—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00252	0.00414	CcSEcCtD
Montelukast—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00249	0.00409	CcSEcCtD
Montelukast—Dyspepsia—Fludarabine—lymphatic system cancer	0.00248	0.00407	CcSEcCtD
Montelukast—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00246	0.00405	CcSEcCtD
Montelukast—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00243	0.00399	CcSEcCtD
Montelukast—Fatigue—Fludarabine—lymphatic system cancer	0.00243	0.00399	CcSEcCtD
Montelukast—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00241	0.00396	CcSEcCtD
Montelukast—Hallucination—Vincristine—lymphatic system cancer	0.00241	0.00396	CcSEcCtD
Montelukast—Pain—Fludarabine—lymphatic system cancer	0.00241	0.00395	CcSEcCtD
Montelukast—Vasculitis—Methotrexate—lymphatic system cancer	0.0024	0.00394	CcSEcCtD
Montelukast—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00239	0.00393	CcSEcCtD
Montelukast—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00238	0.00391	CcSEcCtD
Montelukast—Urethral disorder—Vincristine—lymphatic system cancer	0.00237	0.0039	CcSEcCtD
Montelukast—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00236	0.00388	CcSEcCtD
Montelukast—Hypersensitivity—Teniposide—lymphatic system cancer	0.00236	0.00388	CcSEcCtD
Montelukast—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00236	0.00387	CcSEcCtD
Montelukast—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00234	0.00384	CcSEcCtD
Montelukast—Asthenia—Teniposide—lymphatic system cancer	0.0023	0.00377	CcSEcCtD
Montelukast—Pruritus—Teniposide—lymphatic system cancer	0.00226	0.00372	CcSEcCtD
Montelukast—Cardiac disorder—Vincristine—lymphatic system cancer	0.00225	0.00369	CcSEcCtD
Montelukast—Body temperature increased—Fludarabine—lymphatic system cancer	0.00222	0.00365	CcSEcCtD
Montelukast—Mental disorder—Carmustine—lymphatic system cancer	0.00222	0.00365	CcSEcCtD
Montelukast—Cough—Bleomycin—lymphatic system cancer	0.00221	0.00362	CcSEcCtD
Montelukast—Diarrhoea—Teniposide—lymphatic system cancer	0.00219	0.0036	CcSEcCtD
Montelukast—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00218	0.00358	CcSEcCtD
Montelukast—Myalgia—Bleomycin—lymphatic system cancer	0.00215	0.00354	CcSEcCtD
Montelukast—Mental disorder—Vincristine—lymphatic system cancer	0.00212	0.00348	CcSEcCtD
Montelukast—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00207	0.00341	CcSEcCtD
Montelukast—Tremor—Carmustine—lymphatic system cancer	0.00207	0.0034	CcSEcCtD
Montelukast—Oedema—Bleomycin—lymphatic system cancer	0.00206	0.00339	CcSEcCtD
Montelukast—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00206	0.00339	CcSEcCtD
Montelukast—Infection—Bleomycin—lymphatic system cancer	0.00205	0.00337	CcSEcCtD
Montelukast—Vomiting—Teniposide—lymphatic system cancer	0.00204	0.00334	CcSEcCtD
Montelukast—Agitation—Carmustine—lymphatic system cancer	0.00203	0.00333	CcSEcCtD
Montelukast—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00202	0.00332	CcSEcCtD
Montelukast—Asthenia—Fludarabine—lymphatic system cancer	0.00202	0.00332	CcSEcCtD
Montelukast—Rash—Teniposide—lymphatic system cancer	0.00202	0.00332	CcSEcCtD
Montelukast—Dermatitis—Teniposide—lymphatic system cancer	0.00202	0.00331	CcSEcCtD
Montelukast—Headache—Teniposide—lymphatic system cancer	0.00201	0.0033	CcSEcCtD
Montelukast—Pruritus—Fludarabine—lymphatic system cancer	0.00199	0.00327	CcSEcCtD
Montelukast—Agitation—Vincristine—lymphatic system cancer	0.00194	0.00318	CcSEcCtD
Montelukast—Diarrhoea—Fludarabine—lymphatic system cancer	0.00192	0.00316	CcSEcCtD
Montelukast—Convulsion—Carmustine—lymphatic system cancer	0.00191	0.00314	CcSEcCtD
Montelukast—Nausea—Teniposide—lymphatic system cancer	0.0019	0.00312	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00188	0.00309	CcSEcCtD
Montelukast—Myalgia—Carmustine—lymphatic system cancer	0.00188	0.00309	CcSEcCtD
Montelukast—Anxiety—Carmustine—lymphatic system cancer	0.00187	0.00308	CcSEcCtD
Montelukast—Paraesthesia—Bleomycin—lymphatic system cancer	0.00185	0.00304	CcSEcCtD
Montelukast—Convulsion—Vincristine—lymphatic system cancer	0.00182	0.003	CcSEcCtD
Montelukast—Oedema—Carmustine—lymphatic system cancer	0.0018	0.00296	CcSEcCtD
Montelukast—Myalgia—Vincristine—lymphatic system cancer	0.00179	0.00295	CcSEcCtD
Montelukast—Cough—Mitoxantrone—lymphatic system cancer	0.00179	0.00294	CcSEcCtD
Montelukast—Infection—Carmustine—lymphatic system cancer	0.00179	0.00294	CcSEcCtD
Montelukast—Vomiting—Fludarabine—lymphatic system cancer	0.00179	0.00294	CcSEcCtD
Montelukast—Convulsion—Mitoxantrone—lymphatic system cancer	0.00178	0.00292	CcSEcCtD
Montelukast—Rash—Fludarabine—lymphatic system cancer	0.00177	0.00292	CcSEcCtD
Montelukast—Dermatitis—Fludarabine—lymphatic system cancer	0.00177	0.00291	CcSEcCtD
Montelukast—Pain—Bleomycin—lymphatic system cancer	0.00176	0.0029	CcSEcCtD
Montelukast—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00176	0.0029	CcSEcCtD
Montelukast—Headache—Fludarabine—lymphatic system cancer	0.00176	0.0029	CcSEcCtD
Montelukast—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00175	0.00287	CcSEcCtD
Montelukast—Myalgia—Mitoxantrone—lymphatic system cancer	0.00175	0.00287	CcSEcCtD
Montelukast—Anxiety—Mitoxantrone—lymphatic system cancer	0.00174	0.00286	CcSEcCtD
Montelukast—Oedema—Vincristine—lymphatic system cancer	0.00172	0.00282	CcSEcCtD
Montelukast—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00172	0.00282	CcSEcCtD
Montelukast—Infection—Vincristine—lymphatic system cancer	0.00171	0.00281	CcSEcCtD
Montelukast—Nervous system disorder—Vincristine—lymphatic system cancer	0.00169	0.00277	CcSEcCtD
Montelukast—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00168	0.00277	CcSEcCtD
Montelukast—Oedema—Mitoxantrone—lymphatic system cancer	0.00167	0.00275	CcSEcCtD
Montelukast—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00167	0.00275	CcSEcCtD
Montelukast—Nausea—Fludarabine—lymphatic system cancer	0.00167	0.00275	CcSEcCtD
Montelukast—Infection—Mitoxantrone—lymphatic system cancer	0.00166	0.00273	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00164	0.0027	CcSEcCtD
Montelukast—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00164	0.00269	CcSEcCtD
Montelukast—Urticaria—Bleomycin—lymphatic system cancer	0.00164	0.00269	CcSEcCtD
Montelukast—Body temperature increased—Bleomycin—lymphatic system cancer	0.00163	0.00268	CcSEcCtD
Montelukast—Insomnia—Carmustine—lymphatic system cancer	0.00163	0.00268	CcSEcCtD
Montelukast—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00163	0.00267	CcSEcCtD
Montelukast—Irritability—Methotrexate—lymphatic system cancer	0.00162	0.00266	CcSEcCtD
Montelukast—Paraesthesia—Carmustine—lymphatic system cancer	0.00162	0.00266	CcSEcCtD
Montelukast—Somnolence—Carmustine—lymphatic system cancer	0.0016	0.00263	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00157	0.00257	CcSEcCtD
Montelukast—Insomnia—Vincristine—lymphatic system cancer	0.00155	0.00255	CcSEcCtD
Montelukast—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00155	0.00255	CcSEcCtD
Montelukast—Paraesthesia—Vincristine—lymphatic system cancer	0.00154	0.00254	CcSEcCtD
Montelukast—Pain—Carmustine—lymphatic system cancer	0.00154	0.00253	CcSEcCtD
Montelukast—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00153	0.00251	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00153	0.00251	CcSEcCtD
Montelukast—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00152	0.0025	CcSEcCtD
Montelukast—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0015	0.00247	CcSEcCtD
Montelukast—Somnolence—Mitoxantrone—lymphatic system cancer	0.00149	0.00245	CcSEcCtD
Montelukast—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00148	0.00244	CcSEcCtD
Montelukast—Fatigue—Vincristine—lymphatic system cancer	0.00148	0.00244	CcSEcCtD
Montelukast—Asthenia—Bleomycin—lymphatic system cancer	0.00148	0.00243	CcSEcCtD
Montelukast—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00147	0.00242	CcSEcCtD
Montelukast—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00147	0.00242	CcSEcCtD
Montelukast—Pain—Vincristine—lymphatic system cancer	0.00147	0.00242	CcSEcCtD
Montelukast—Asthma—Methotrexate—lymphatic system cancer	0.00147	0.00241	CcSEcCtD
Montelukast—Pruritus—Bleomycin—lymphatic system cancer	0.00146	0.0024	CcSEcCtD
Montelukast—Eosinophilia—Methotrexate—lymphatic system cancer	0.00145	0.00239	CcSEcCtD
Montelukast—Fatigue—Mitoxantrone—lymphatic system cancer	0.00144	0.00237	CcSEcCtD
Montelukast—Pancreatitis—Methotrexate—lymphatic system cancer	0.00144	0.00236	CcSEcCtD
Montelukast—Pain—Mitoxantrone—lymphatic system cancer	0.00143	0.00235	CcSEcCtD
Montelukast—Abdominal pain—Carmustine—lymphatic system cancer	0.00142	0.00234	CcSEcCtD
Montelukast—Body temperature increased—Carmustine—lymphatic system cancer	0.00142	0.00234	CcSEcCtD
Montelukast—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00141	0.00231	CcSEcCtD
Montelukast—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00137	0.00225	CcSEcCtD
Montelukast—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00136	0.00224	CcSEcCtD
Montelukast—Body temperature increased—Vincristine—lymphatic system cancer	0.00136	0.00223	CcSEcCtD
Montelukast—Abdominal pain—Vincristine—lymphatic system cancer	0.00136	0.00223	CcSEcCtD
Montelukast—Urticaria—Mitoxantrone—lymphatic system cancer	0.00133	0.00219	CcSEcCtD
Montelukast—Hypersensitivity—Carmustine—lymphatic system cancer	0.00133	0.00218	CcSEcCtD
Montelukast—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00132	0.00217	CcSEcCtD
Montelukast—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00132	0.00217	CcSEcCtD
Montelukast—Pneumonia—Methotrexate—lymphatic system cancer	0.00132	0.00216	CcSEcCtD
Montelukast—Vomiting—Bleomycin—lymphatic system cancer	0.00131	0.00216	CcSEcCtD
Montelukast—Infestation NOS—Methotrexate—lymphatic system cancer	0.00131	0.00215	CcSEcCtD
Montelukast—Infestation—Methotrexate—lymphatic system cancer	0.00131	0.00215	CcSEcCtD
Montelukast—Drowsiness—Methotrexate—lymphatic system cancer	0.00131	0.00215	CcSEcCtD
Montelukast—Rash—Bleomycin—lymphatic system cancer	0.0013	0.00214	CcSEcCtD
Montelukast—Dermatitis—Bleomycin—lymphatic system cancer	0.0013	0.00214	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.0013	0.00213	CcSEcCtD
Montelukast—Asthenia—Carmustine—lymphatic system cancer	0.00129	0.00212	CcSEcCtD
Montelukast—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00127	0.00209	CcSEcCtD
Montelukast—Hypersensitivity—Vincristine—lymphatic system cancer	0.00127	0.00208	CcSEcCtD
Montelukast—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00124	0.00203	CcSEcCtD
Montelukast—Epistaxis—Methotrexate—lymphatic system cancer	0.00123	0.00203	CcSEcCtD
Montelukast—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00123	0.00203	CcSEcCtD
Montelukast—Asthenia—Vincristine—lymphatic system cancer	0.00123	0.00203	CcSEcCtD
Montelukast—Diarrhoea—Carmustine—lymphatic system cancer	0.00123	0.00202	CcSEcCtD
Montelukast—Nausea—Bleomycin—lymphatic system cancer	0.00123	0.00201	CcSEcCtD
Montelukast—Asthenia—Mitoxantrone—lymphatic system cancer	0.0012	0.00197	CcSEcCtD
Montelukast—Dizziness—Carmustine—lymphatic system cancer	0.00119	0.00196	CcSEcCtD
Montelukast—Diarrhoea—Vincristine—lymphatic system cancer	0.00118	0.00193	CcSEcCtD
Montelukast—Hepatitis—Methotrexate—lymphatic system cancer	0.00117	0.00193	CcSEcCtD
Montelukast—Pharyngitis—Methotrexate—lymphatic system cancer	0.00117	0.00191	CcSEcCtD
Montelukast—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00116	0.00191	CcSEcCtD
Montelukast—Urethral disorder—Methotrexate—lymphatic system cancer	0.00115	0.00189	CcSEcCtD
Montelukast—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00115	0.00188	CcSEcCtD
Montelukast—Vomiting—Carmustine—lymphatic system cancer	0.00114	0.00188	CcSEcCtD
Montelukast—Dizziness—Vincristine—lymphatic system cancer	0.00114	0.00187	CcSEcCtD
Montelukast—Rash—Carmustine—lymphatic system cancer	0.00114	0.00187	CcSEcCtD
Montelukast—Dermatitis—Carmustine—lymphatic system cancer	0.00113	0.00186	CcSEcCtD
Montelukast—Headache—Carmustine—lymphatic system cancer	0.00113	0.00185	CcSEcCtD
Montelukast—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00111	0.00182	CcSEcCtD
Montelukast—Vomiting—Vincristine—lymphatic system cancer	0.00109	0.0018	CcSEcCtD
Montelukast—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00109	0.00179	CcSEcCtD
Montelukast—Rash—Vincristine—lymphatic system cancer	0.00108	0.00178	CcSEcCtD
Montelukast—Dermatitis—Vincristine—lymphatic system cancer	0.00108	0.00178	CcSEcCtD
Montelukast—Headache—Vincristine—lymphatic system cancer	0.00108	0.00177	CcSEcCtD
Montelukast—Nausea—Carmustine—lymphatic system cancer	0.00107	0.00176	CcSEcCtD
Montelukast—Vomiting—Mitoxantrone—lymphatic system cancer	0.00106	0.00175	CcSEcCtD
Montelukast—Immune system disorder—Methotrexate—lymphatic system cancer	0.00106	0.00174	CcSEcCtD
Montelukast—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00106	0.00174	CcSEcCtD
Montelukast—Rash—Mitoxantrone—lymphatic system cancer	0.00106	0.00173	CcSEcCtD
Montelukast—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00105	0.00173	CcSEcCtD
Montelukast—Headache—Mitoxantrone—lymphatic system cancer	0.00105	0.00172	CcSEcCtD
Montelukast—Mental disorder—Methotrexate—lymphatic system cancer	0.00103	0.00169	CcSEcCtD
Montelukast—Nausea—Vincristine—lymphatic system cancer	0.00102	0.00168	CcSEcCtD
Montelukast—Nausea—Mitoxantrone—lymphatic system cancer	0.000994	0.00163	CcSEcCtD
Montelukast—Cough—Methotrexate—lymphatic system cancer	0.000892	0.00147	CcSEcCtD
Montelukast—Convulsion—Methotrexate—lymphatic system cancer	0.000885	0.00145	CcSEcCtD
Montelukast—Myalgia—Methotrexate—lymphatic system cancer	0.00087	0.00143	CcSEcCtD
Montelukast—Arthralgia—Methotrexate—lymphatic system cancer	0.00087	0.00143	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000864	0.00142	CcSEcCtD
Montelukast—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000834	0.00137	CcSEcCtD
Montelukast—Infection—Methotrexate—lymphatic system cancer	0.000829	0.00136	CcSEcCtD
Montelukast—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000818	0.00134	CcSEcCtD
Montelukast—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000817	0.00134	CcSEcCtD
Montelukast—Skin disorder—Methotrexate—lymphatic system cancer	0.00081	0.00133	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00076	0.00125	CcSEcCtD
Montelukast—Insomnia—Methotrexate—lymphatic system cancer	0.000754	0.00124	CcSEcCtD
Montelukast—Paraesthesia—Methotrexate—lymphatic system cancer	0.000749	0.00123	CcSEcCtD
Montelukast—Somnolence—Methotrexate—lymphatic system cancer	0.000741	0.00122	CcSEcCtD
Montelukast—Dyspepsia—Methotrexate—lymphatic system cancer	0.000734	0.00121	CcSEcCtD
Montelukast—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00072	0.00118	CcSEcCtD
Montelukast—Fatigue—Methotrexate—lymphatic system cancer	0.000719	0.00118	CcSEcCtD
Montelukast—Pain—Methotrexate—lymphatic system cancer	0.000713	0.00117	CcSEcCtD
Montelukast—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000682	0.00112	CcSEcCtD
Montelukast—Urticaria—Methotrexate—lymphatic system cancer	0.000663	0.00109	CcSEcCtD
Montelukast—Abdominal pain—Methotrexate—lymphatic system cancer	0.000659	0.00108	CcSEcCtD
Montelukast—Body temperature increased—Methotrexate—lymphatic system cancer	0.000659	0.00108	CcSEcCtD
Montelukast—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000614	0.00101	CcSEcCtD
Montelukast—Asthenia—Methotrexate—lymphatic system cancer	0.000598	0.000983	CcSEcCtD
Montelukast—Pruritus—Methotrexate—lymphatic system cancer	0.00059	0.00097	CcSEcCtD
Montelukast—Diarrhoea—Methotrexate—lymphatic system cancer	0.000571	0.000938	CcSEcCtD
Montelukast—Dizziness—Methotrexate—lymphatic system cancer	0.000552	0.000906	CcSEcCtD
Montelukast—Vomiting—Methotrexate—lymphatic system cancer	0.00053	0.000871	CcSEcCtD
Montelukast—Rash—Methotrexate—lymphatic system cancer	0.000526	0.000864	CcSEcCtD
Montelukast—Dermatitis—Methotrexate—lymphatic system cancer	0.000525	0.000863	CcSEcCtD
Montelukast—Headache—Methotrexate—lymphatic system cancer	0.000522	0.000859	CcSEcCtD
Montelukast—Nausea—Methotrexate—lymphatic system cancer	0.000495	0.000814	CcSEcCtD
